Sarmiento-Chavero M, Herrera-Bello H, Herrera-Gomar M, Idelfonso PR

Language: Spanish
References: 23
Page: 114-116
PDF size: 146.88 Kb.

ABSTRACT

Cardiotoxicity is one of the main causes of death and impairment in patients with lymphoma who were treated with chemotherapy and/ or radiotherapy. The survival in this type of neoplasm has improved in the last decade, leading us to rethink the way in which we evaluate and face the short and long term adverse effects. In the case of cardiotoxicity by anthracyclines, despite knowing about it many years ago, we still have no answer on the best way to predict or prevent it. In some cases, as in the treatment of lymphoma diffuse large cell B without further specification or breast cancer, is chosen to combine several cardiotoxic therapies. Actually there is now interest in developing methods for detecting not only an early damage, but to distinguish between the damage produced by different components of the treatment.

REFERENCES

1. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol 2010 (s7): 173-9.

2. Singal PK, Iliskovic N. Doxorubicin induced cardiomyopathy. NEJM 1998; (24): 900-4.

3. Yoon GY, Telli ML, Kao DP, Matsuda KY, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. J Am Coll Cardiol 2010; 56(20): 1647-50.

4. Ewer S, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Safety 2008; 31(6): 459-67.

5. Mellor HR, Bell AR, Valentin JR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011; 120(1): 14-32.

6. Gupta R, Maitland ML. Sunitinib, hipertensión, and heart failure: A model for kinase inhibitor mediated cardiotoxicity. Curr Hypertens Rep 2011; 13(6): 430-5.

7. Pantaleo MA, Mandrioli A, Saponara M. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012.

8. Sandra MS, Frederick SW, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97(11): 2869-79.

9. Edward TH, Ann TT, Daniel JL, Wamique Yusaf, et al. Cardiovascular complications of cancer therapy: Diagnosis, patogénesis and Management. Circulation 2004; 109: 3122-31.

10. Albi A, Pennesi G, Donatelli F, Cammarota R. Cardiotoxicity of anticancer drugs: The need for cardio oncology and cardio oncological prevention. J Natl Cancer Inst 2010; 2010(102): 14-25.

11. Cardinale D, Colombo A, Lamantina G, Colombo N, et al. Anthraycline induced cardiomyopathy. J Am Coll Cardiol 2010; 55(3): 213-9.

12. Khasraw M, Bell R, Dang Ch. Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. The Breast 2012; 1: 1-8.

13. Zenaide Quezado, Wyndham H. Wilson Robert E. Cunnion, et al. High dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993: 118(1): 31-6.

14. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Comitee of the Childrens Cancer Study Group. Padiatrics 1992; 89; 942.

15. Bovelli D, Platonitis G, Riola F. Cardiotoxicitiy of chemotherapeutic agents and radiotherapy related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010; 2010 (5): 277-82.

16. Altena R, Perik PJ, Van Veldhuisen DJ. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-9.

17. Romano, Frantini S, Ricevuto E, Procaccini V, et al. Serial mesurments of NT proBNP are predicitve of anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105 (11): 1663-8.

18. Feola M, Garrone O, Ocelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effect on left ventricular ejection fraction, Troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148: 194–8.

19. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-Trastuzumab interaction. J Clin Oncol 2010; 28(25): 3901-4.

20. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline and trastuzumab induced cardiotoxicity in the long term follow up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010; 701-7.

21. Fallah–Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with Her2 positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57 (22): 2263-70.

22. Edvardsen T. Can Modern echocardiographic techniques predict drug induced cardiotoxicity. J Am Coll Cardiol 2011; 57(22): 2271-2.

23. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 2011; 22: 1011-8.